Journal of Clinical Pediatrics >
Construction and validation of the prognosis nomogram of pediatric medulloblastoma based on clinical and tumor biological characteristics
Received date: 2021-09-26
Online published: 2022-07-08
Objective To identify potential prognostic markers of pediatric medulloblastoma (MB) in immunohistochemical results, and to construct a risk stratification system based on the integration of clinical characteristics, so as to guide the postoperative personalized management of MB children. Methods The clinical data of children with MB undergoing resection from January 1, 2011 to August 1, 2020 were retrospectively analyzed, and the logistic regression model was constructed to predict the short-term outcomes (STO) (postoperative tumor residue). The children were divided into high-risk group and low-risk group according to postoperative STO and imaging metastasis characteristics. The COX regression model was used to analyze the independent risk factors for long-term outcome (LTO) including recurrence, reoperation and survival. R software was used to construct the nomogram, and the nomogram was evaluated by C-index, calibration curve and decision curve analysis (DCA). Results A total of 111 children (67 boys and 44 girls) with MB were included, with a median age of 7.0 (4.0-9.0) years. Tumor diameter >5.0 cm (OR=8.07, 95% CI: 2.62-24.89) and MYC protein expression (OR=4.03, 95% CI: 1.29-12.63) can predict STO (AUC=0.81, 95% CI: 0.69-0.92, P<0.001). The 12-month LTO-free survival (LOFS) of the high-risk group (n=50) was 76.0% (95% CI: 70.0%-82.0%), and that of the low-risk group (n=61) was 83.6% (95% CI: 78.9% -88.3%). The difference between the two groups was statistically significant (HR=2.77, 95% CI: 1.53-5.01). COX regression model showed that risk grouping, age≤3 years, diameter>5.0 cm, and MYC positive were independent risk factors for poor LTO (P<0.05). Based on the above clinical-biological independent risk factors, LOFS can be accurately predicted by establishing a nomogram, with a C-index of 0.715. Moreover, the calibration curve showed a high degree of consistency between the predicted risk and the actual risk. The net benefit was good in DCA for a wide range of prediction probabilities, demonstrating a good clinical utility. Conclusions The nomogram constructed based on risk grouping, age, tumor diameter and MYC are conducive to the targeted monitoring and management of pediatric MB.
Key words： medulloblastoma; prognosis; nomogram
Zaiyu ZHANG , Ping LIANG . Construction and validation of the prognosis nomogram of pediatric medulloblastoma based on clinical and tumor biological characteristics[J]. Journal of Clinical Pediatrics, 2022 , 40(7) : 527 -533 . DOI: 10.12372/jcp.2022.21e1377
| [1] | Ostrom QT, Cioffi G, Waite K, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018[J]. Neuro Oncol, 2021, 23(12 Suppl 2): iii1-iii105. |
| [2] | Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas[J]. Radiology, 1969, 93(6): 1351-1359. |
| [3] | Thomas A, Noël G. Medulloblastoma: optimizing care with a multidisciplinary approach[J]. J Multidiscip Healthc, 2019, 12: 335-347. |
| [4] | Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251. |
| [5] | Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2): 97-109. |
| [6] | Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820. |
| [7] | Carvalho RM, Pinto GR, Yoshioka FK, et al. Prognostic value of the TP53 Arg72Pro single-nucleotide poly-morphism and susceptibility to medulloblastoma in a cohort of Brazilian patients[J]. J Neurooncol, 2012, 110(1): 49-57. |
| [8] | de Haas T, Hasselt N, Troost D, et al. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression[J]. Clin Cancer Res, 2008, 14(13): 4154-4160. |
| [9] | Gajjar A, Robinson GW, Smith KS, et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)[J]. J Clin Oncol, 2021, 39(7): 822-835. |
| [10] | Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis[J]. Lancet Oncol, 2016, 17(4): 484-495. |
| [11] | Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization[J]. Clin Cancer Res, 2004, 10(21): 7252-7259. |
| [12] | Akaike H. A new look at the statistical model identification[M/OL]. Selected Papers of Hirotugu Akaike. Springer Series in Statistics. Springer, New York, NY. http://doi.org/10.1007/12-1694-0_16. |
| [13] | Van Calster B, Wynants L, Verbeek JFM, et al. Reporting and interpreting decision curve analysis: a guide for investigators[J]. Eur Urol, 2018, 74(6): 796-804. |
| [14] | Huybrechts S, Le Teuff G, Tauziède-Espariat A, et al. Prognostic clinical and biologic features for overall survival after relapse in childhood medulloblastoma[J]. Cancers (Basel), 2020, 13(1): 53. |
| [15] | Hill RM, Richardson S, Schwalbe EC, et al. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study[J]. Lancet Child Adolescent Health, 2020, 4(12): 865-874. |
| [16] | Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study[J]. J Clin Oncol, 1999, 17(3): 832-845. |
| [17] | Kortmann RD, Kühl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91[J]. Int J Radiat Oncol Biol Phys, 2000, 46(2): 269-279. |
| [18] | Taylor RE, Bailey CC, Robinson KJ, et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy[J]. Eur J Cancer, 2005, 41(5): 727-734. |
| [19] | Lee JW, Lim DH, Sung KW, et al. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma[J]. Cancer Med, 2020, 9(16): 5807-5818. |
| [20] | Dietzsch S, Placzek F, Pietschmann K, et al. Evaluation of prognostic factors and role of participation in a randomized trial or a prospective registry in pediatric and adolescent nonmetastatic medulloblastoma - a report from the HIT 2000 trial[J]. Adv Radiat Oncol, 2020, 5(6): 1158-1169. |
| [21] | Dhall G, O'Neil SH, Ji L, et al. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial[J]. Neuro Oncol, 2020, 22(12): 1862-1872. |
| [22] | AL-Afif S, Krauss JK, Helms F, et al. Long-term impairment of social behavior, vocalizations and motor activity induced by bilateral lesions of the fastigial nucleus in juvenile rats[J]. Brain Struct Funct, 2019, 224(5): 1739-1751. |
| [23] | Hoche F, Guell X, Vangel MG, et al. The cerebellar cognitive affective/Schmahmann syndrome scale[J]. Brain, 2018, 141(1): 248-270. |
| [24] | Lanier JC, Abrams AN. Posterior fossa syndrome: review of the behavioral and emotional aspects in pediatric cancer patients[J]. Cancer, 2017, 123(4): 551-559. |
| [25] | von Hoff K, Hartmann W, von Bueren AO, et al. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors[J]. Pediatr Blood Cancer, 2010, 54(3): 369-376. |
| [26] | Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma[J]. Acta Neuropathol, 2012, 123(4): 501-513. |
| [27] | Srivastava VK, Nalbantoglu J. The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics[J]. Cancer Biol Ther, 2010, 9(11): 843-852. |
| [28] | Ray A, Ho M, Ma J, et al. A clinicobiological model predicting survival in medulloblastoma[J]. Clin Cancer Res, 2004, 10(22): 7613-7620. |
| [29] | Korshunov A, Savostikova M, Ozerov S. Immuno-histochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression[J]. J Neurooncol, 2002, 58(3): 271-279. |
/
| 〈 |
|
〉 |
